[Characterization of amyloidosis].
Masahide Yazaki1, Shu-Ichi Ikeda
1Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|July 8, 2014
Summary
Amyloidosis causes organ failure from amyloid protein buildup. Effective therapies may reverse tissue amyloid deposits, offering hope for treating these progressive conditions.
Area of Science:
- Biochemistry
- Pathology
- Medical Science
Context:
- Amyloidosis is characterized by the deposition of amyloid proteins in organs, leading to organ failure.
- Diagnostic methods include Congo red staining and apple-green birefringence under polarized light.
- Amyloid fibril proteins are highly stable, yet recent research indicates a dynamic turnover process.
Purpose:
- To review the understanding of amyloid deposition and clearance in amyloidosis.
- To explore the potential for therapeutic regression of tissue-deposited amyloid.
- To highlight the implications for treating specific amyloidosis types.
Summary:
- Amyloidosis involves organ damage from amyloid protein accumulation.
- Despite protein stability, amyloid deposits undergo turnover, influenced by deposition and clearance mechanisms.
- This dynamic suggests therapeutic interventions can promote amyloid regression.
Impact:
- Effective therapies targeting amyloid turnover could lead to regression of tissue deposits.
- This offers a potential treatment strategy for primary AL, reactive AA, and transthyretin-related amyloidosis.
- Successful regression could significantly improve patient outcomes and organ function.
Related Concept Videos
03:03Amyloid Fibrils
5.2K
5.2K
03:03Amyloid Fibrils
10.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.1K
01:23Alzheimer Disease ll: Pathophysiology
27
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
27
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Myasthenia Gravis ll: Pathophysiology
44
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
44
01:29Alzheimer Disease l: Introduction
19
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
19